Table 1 Clinical and Demographic Characteristics of Patients with BSI Caused by E. coli
Univariate analysis | Multivariable analysis | ||||||
|---|---|---|---|---|---|---|---|
Non- ESBL- producing E. coli | ESBL- producing E. coli | P-values | P-values | OR | 95% CI for OR | ||
(n = 208) | (n = 283) | Lower | Upper | ||||
Demographic | |||||||
Male, n (%) | 112 (53.8) | 150 (53.0) | 0.853 | ||||
Age, mean ± SD | 60.8 ± 16.7 | 60.5 ± 16.3 | 0.836 | ||||
Total hospital stay, days (median, IQR) | 19 (11–28) | 18 (11–37) | 0.188 | ||||
Hospital stay before BSI, days (median, IQR) | 3 (0–13) | 4 (1–14) | 0.336 | ||||
ICU stay prior to BSIa | 11 (5.3) | 25 (8.8) | 0.136 | ||||
Preexisting medical conditions | |||||||
Hypertension | 58 (27.9) | 80 (28.3) | 0.925 | ||||
Diabetes | 34 (16.4) | 45 (15.9) | 0.876 | ||||
Lung disease | 2 (1.0) | 6 (2.1) | 0.477 | ||||
Cardiovascular diseases | 4 (1.9) | 7 (2.5) | 0.921 | ||||
Hepatobiliary disease | 59 (28.4) | 78 (27.6) | 0.844 | ||||
Urinary system disease | 15 (7.2) | 25 (8.8) | 0.516 | ||||
Nervous system disease | 7 (3.4) | 8 (2.8) | 0.732 | ||||
Malignant solid tumor | 43 (20.7) | 63 (22.3) | 0.673 | ||||
Hematological Disease | 39 (18.8) | 35 (12.4) | 0.051 | ||||
Charlson comorbidity score c (median, IQR) | 2 (0–2) | 2 (0–2) | 0.168 | ||||
Likely source of BSI | |||||||
Central vein Catheter-related infections | 7.2 (7.2) | 10 (3.5) | 0.067 | ||||
Lung infection | 52 (25.0) | 56 (19.8) | 0.168 | ||||
Abdominal infection | 108 (51.9) | 141 (49.8) | 0.646 | ||||
Urinary infection | 26 (12.5) | 58 (20.5) | 0.020 | 0.014 | 1.897 | 1.138 | 3.164 |
Intracranial infection | 1 (0.5) | 4 (1.4) | 0.402 | ||||
Skin infection | 6 (2.9) | 11(3.9) | 0.548 | ||||
Primary bloodstream infection | 19 (9.1) | 26 (9.2) | 0.984 | ||||
Nosocomial-acquired infection | 124 (59.6) | 180 (63.6) | 0.368 | ||||
Hospitalization prior to BSIb | 75 (56.0) | 110 (59.1) | 0.571 | ||||
Surgery prior to BSIa | 27 (13.0) | 56 (19.8) | 0.047 | ||||
Invasive procedure and/or devices prior to BSIa | 46 (22.1) | 83 (29.3) | 0.073 | ||||
Mechanical ventilation | 7 (3.4) | 11 (3.9) | 0.761 | ||||
Central venous catheterization | 20 (9.6) | 42 (14.8) | 0.085 | ||||
Urinary catheterization | 18 (8.7) | 42 (14.8) | 0.039 | ||||
Gastric catheterization | 10 (4.8) | 31(11.0) | 0.015 | ||||
Percutaneous catheterization | 6 (2.9) | 21 (7.4) | 0.029 | 0.101 | 2.218 | 0.857 | 5.742 |
Hemodialysis prior to BSIa | 6 (2.9) | 3 (1.1) | 0.251 | ||||
Chemotherapy or radiotherapy prior to BSIa | 38 (18.3) | 39 (13.8) | 0.177 | ||||
Corticosteroid use prior to BSIa | 15 (7.2) | 21 (7.4) | 0.930 | ||||
Immunosuppressant use prior to BSIa | 1 (0.5) | 2 (0.7) | > 0.050 | ||||
Antibiotics use prior to BSIa | 68 (32.7) | 134 (47.3) | 0.001 | ||||
Cepholosporins | 10 (4.8) | 38 (13.4) | 0.001 | 0.007 | 2.767 | 1.325 | 5.779 |
BLBLI combination antibiotics | 26 (12.5) | 62 (21.9) | 0.007 | 0.010 | 1.950 | 1.173 | 3.241 |
Tigecycline | 2 (1.0) | 3 (1.1) | > 0.050 | ||||
Carbapenems | 17 (8.2) | 20 (7.1) | 0.646 | ||||
Aminoglycosides | 1 (0.5) | 2 (0.7) | > 0.050 | ||||
Quinolones | 26 (12.5) | 36 (12.7) | 0.942 | ||||
Laboratory examination | |||||||
White blood cell | 8.1 (3.8–13.0) | 9.6 (5.5–14.8) | 0.045 | ||||
Platelet (median, IQR) | 104 (42–183) | 117 (58–192) | 0.161 | ||||
Serum total protein (median, IQR) | 57.7 (52.0–64.7) | 58.3 (52.3–64.3) | 0.949 | ||||
Severity of illness | |||||||
APACHEII score (median, IQR) | 9 (6–12) | 9 (6–13) | 0.540 | ||||
Appropriate empirical treatment after BSI | 200 (96.2) | 249 (88.3) | 0.001 | ||||
Appropriate definitive treatments after BSI | 204 (98.1) | 267 (94.3) | 0.039 | ||||
7-day mortality | 17 (8.2) | 24 (8.1) | 0.985 | ||||
14-day mortality | 23 (11.1) | 28 (9.9) | 0.676 | ||||
28-day mortality | 29 (13.9) | 42 (14.8) | 0.780 | ||||